What is added by this article?
The article describes recent efforts made by Australia, Canada, England, the Netherlands, Scotland and the United States to expand the role of community pharmacists. The authors analyzed levels of policy development within these countries with regards to roles, objectives, and incentives for health professionals and the expanded role of community pharmacists. While other countries have more developed policies on this matter, a look at countries whose policies are evolving can be valuable.
National experts from each of these six countries were surveyed about the current role of community pharmacists, the economic and political climate in which the community pharmacists work, policy developments regarding the effective, safe, and efficient use of medicines and the prevention and management of chronic disease, and evaluation efforts. The experts were selected based on their advocacy for community pharmacists, knowledge of the latest policy developments, and their research on the evaluation of ongoing policy initiatives surrounding the expanded roles of the community pharmacists.
All of the countries have a number of policies in place to promote effective, safe, and appropriate use of medicines. The authors looked at eight domains for each country:
National Center for Chronic Disease Prevention and Health Promotion Division of Heart Disease and Stroke Prevention They found wide variation in each domain. England and Scotland are at the forefront of expanding the role of community pharmacists in this group of six countries through their use of "tiers" to frame the extent of pharmacists' work in safe medication use and in chronic disease management. U.S. law does not allow for community pharmacists to administer drugs via injections. Australia does not have a policy in place on changing drug dosage/formulation, therapeutic substitutions, or initiating prescription drug therapy. The Netherlands has no policy for community pharmacists to make therapeutic substitutions, write prescriptions for minor ailments, or initiate prescription drug therapy. Because of the nature of Canada's legal system, only certain provinces have adopted changes in some of these domains.
Involving pharmacists in the management of chronic conditions has been slow, but Scotland and England have formalized community pharmacists' role in chronic disease management. Australia and Canada are integrating community pharmacists into primary care delivery with collaborative pharmacy reviews and disease management activities; initiatives are led by professional organizations and governmental agencies. In the Netherlands, guidelines have been developed for the transfer of information between pharmacists and other primary and secondary care providers, crucial for appropriate medication use. Policy development in the United States has been limited to the use of community pharmacists to aid in workplace health promotion initiatives.
What are the Implications of these findings?
